Literature DB >> 34782395

Short NK- and Naïve T-Cell Telomere Length Is Associated with Thyroid Cancer in Childhood Cancer Survivors: A Report from the Childhood Cancer Survivor Study.

Tsz-Kwong Man1,2, Geraldine Aubert3,4, Melissa A Richard1,2, Wanda LeJeune1, Elmira Hariri4, Tatiana Goltsova1, Amos Gaikwad1, Yan Chen5, Jillian Whitton6, Wendy M Leisenring6, Michael A Arnold7, Joseph P Neglia8, Yutaka Yasui9, Leslie L Robison9, Gregory T Armstrong9, Smita Bhatia10, Maria M Gramatges11,2.   

Abstract

BACKGROUND: Survivors of childhood cancer are at risk for therapy-related subsequent malignant neoplasms (SMN), including thyroid SMN. Telomere length (TL) is associated with cancer risk, but the relationship between TL and SMN risk among survivors is less clear.
METHODS: We conducted a nested, matched case-control study of radiation-exposed 15-year+ adult survivors of childhood cancer with thyroid SMN (cases) and without SMN (controls). Forty-six cases were matched to 46 controls by primary diagnosis, chemotherapy (yes/no), radiation field, and follow-up duration. Lymphocyte TL (LTL) was measured by telomere flow-FISH cytometry using blood samples banked at a mean of 38.9 years (cases), 39.2 years (controls). Genetic variation in telomere genes was assessed by whole genome sequencing. Point estimates for LTL <10th percentile were determined for cases and controls.
RESULTS: Cases had shorter median LTL than controls in three out of four leukocyte subsets. Cases were more likely to have NK cell LTL <10th percentile (P = 0.01), and 2.8-fold more likely to have naïve T-cell LTL <10th percentile than controls (CI, 1.07-8.78). Five out of 15 cases with a rare indel or missense variant had naïve T-cell LTL <10th percentile, compared with one out of eight controls.
CONCLUSIONS: Long-term survivors have shorter than expected LTL, a finding that is more pronounced among survivors with thyroid SMN. IMPACT: The long-term impact of childhood cancer treatment on immune function is poorly understood. Our findings support immune function studies in larger survivor cohorts to assess long-term deficits in adaptive and innate immunity that may underlie SMN risk. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2021        PMID: 34782395      PMCID: PMC8825729          DOI: 10.1158/1055-9965.EPI-21-0791

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.090


  46 in total

1.  Temporal Trends in Treatment and Subsequent Neoplasm Risk Among 5-Year Survivors of Childhood Cancer, 1970-2015.

Authors:  Lucie M Turcotte; Qi Liu; Yutaka Yasui; Michael A Arnold; Sue Hammond; Rebecca M Howell; Susan A Smith; Rita E Weathers; Tara O Henderson; Todd M Gibson; Wendy Leisenring; Gregory T Armstrong; Leslie L Robison; Joseph P Neglia
Journal:  JAMA       Date:  2017-02-28       Impact factor: 56.272

2.  Telomere length is associated with disease severity and declines with age in dyskeratosis congenita.

Authors:  Blanche P Alter; Philip S Rosenberg; Neelam Giri; Gabriela M Baerlocher; Peter M Lansdorp; Sharon A Savage
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

3.  Haploinsufficiency of telomerase reverse transcriptase leads to anticipation in autosomal dominant dyskeratosis congenita.

Authors:  Mary Armanios; Jiunn-Liang Chen; Yen-Pei Christy Chang; Robert A Brodsky; Anita Hawkins; Constance A Griffin; James R Eshleman; Alan R Cohen; Aravinda Chakravarti; Ada Hamosh; Carol W Greider
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-24       Impact factor: 11.205

4.  Screening for thyroid cancer in survivors of childhood and young adult cancer treated with neck radiation.

Authors:  Emily S Tonorezos; Dana Barnea; Chaya S Moskowitz; Joanne F Chou; Charles A Sklar; Elena B Elkin; Richard J Wong; Duan Li; R Michael Tuttle; Deborah Korenstein; Suzanne L Wolden; Kevin C Oeffinger
Journal:  J Cancer Surviv       Date:  2016-12-27       Impact factor: 4.442

5.  Telomere Length-Associated Genetic Variants and the Risk of Thyroid Cancer in Survivors of Childhood Cancer: A Report from the Childhood Cancer Survivor Study (CCSS).

Authors:  Maria M Gramatges; Lindsay M Morton; Yutaka Yasui; Michael A Arnold; Joseph P Neglia; Wendy M Leisenring; Mitchell J Machiela; Casey L Dagnall; Stephen J Chanock; Gregory T Armstrong; Leslie L Robison; Smita Bhatia; Philip J Lupo
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-10-30       Impact factor: 4.254

Review 6.  Immune function in childhood cancer survivors: a Children's Oncology Group review.

Authors:  Gregory M T Guilcher; Linda Rivard; Jennifer T Huang; Nicola A M Wright; Lynette Anderson; Hesham Eissa; Wendy Pelletier; Shanti Ramachandran; Tal Schechter; Ami J Shah; Ken Wong; Eric J Chow
Journal:  Lancet Child Adolesc Health       Date:  2021-02-16

Review 7.  Biology of premature ageing in survivors of cancer.

Authors:  Margaret C Cupit-Link; James L Kirkland; Kirsten K Ness; Gregory T Armstrong; Tamar Tchkonia; Nathan K LeBrasseur; Saro H Armenian; Kathryn J Ruddy; Shahrukh K Hashmi
Journal:  ESMO Open       Date:  2017-12-18

Review 8.  Thymic Function Associated With Cancer Development, Relapse, and Antitumor Immunity - A Mini-Review.

Authors:  Weikan Wang; Rachel Thomas; Olga Sizova; Dong-Ming Su
Journal:  Front Immunol       Date:  2020-04-30       Impact factor: 7.561

Review 9.  Revisiting the role of CD4+ T cells in cancer immunotherapy-new insights into old paradigms.

Authors:  Rong En Tay; Emma K Richardson; Han Chong Toh
Journal:  Cancer Gene Ther       Date:  2020-05-27       Impact factor: 5.987

10.  The Ensembl Variant Effect Predictor.

Authors:  William McLaren; Laurent Gil; Sarah E Hunt; Harpreet Singh Riat; Graham R S Ritchie; Anja Thormann; Paul Flicek; Fiona Cunningham
Journal:  Genome Biol       Date:  2016-06-06       Impact factor: 13.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.